ETF · real data, updated daily
XBI — Spdr S&P Biotech ETF
Over the last 15 years (2011-06 – 2026-07), $10,000 invested in XBI with dividends reinvested grew to $67,094 — 13.37% a year — with a worst peak-to-trough fall of -56.67%. Past performance doesn't predict future results.
Growth of $10,000 · 2011-06 – 2026-07 · dividends reinvested
About XBI
SPDR S&P Biotech ETF is an exchange-traded fund designed to track an equal-weighted index of U.S. biotechnology stocks. The fund gives investors broad exposure to the biotechnology segment of the healthcare market, with holdings that typically include companies involved in drug discovery, genetic research, therapeutic development, diagnostics, and advanced life sciences tools. Its equal-weighted approach reduces concentration in the largest names and provides more balanced representation across smaller and mid-sized biotech companies. SPDR S&P Biotech ETF is used as a diversified vehicle for gaining exposure to a sector known for innovation, scientific research, and product development across human health and medical technology. Managed by State Street, the fund serves market participants looking for targeted access to the biotech industry through a single pooled portfolio.
Put XBI to the test
Every tool below opens prefilled with XBI — free, no account needed.
Backtest XBI →
Full history, any date range, benchmarks, drawdowns, rolling returns.
Would XBI survive 2008? →
What actually happened to it in the crisis — real drawdown and recovery.
Project it forward →
Monte Carlo simulation of where it could go from here.
Compare XBI vs VTI →
Head-to-head against the total US market.
Replay $100/mo into XBI →
Animated growth of steady monthly contributions.
Fundamentals →
Holdings-level financials where available.
Educational use only — not investment advice. Results are hypothetical.Read full disclaimer
This tool is for educational and informational purposes only and does not provide financial, investment, tax, legal, or accounting advice. Results are hypothetical and based on historical data and assumptions that may be inaccurate. Past performance does not guarantee future results. Consult a licensed professional before making investment decisions.